Genetic test availability and spending: Where are we now? Where are we going?

Kathryn A. Phillips, Patricia A. Deverka, Gillian W. Hooker, Michael P. Douglas

Research output: Contribution to journalArticle

Abstract

Genetic testing and spending on that testing have grown rapidly since the mapping of the human genome in 2003. However, it is not widely known how many tests there are, how they are used, and how they are paid for. Little evidence from large data sets about their use has emerged. We shed light on the issue of genetic testing by providing an overview of the testing landscape. We examined test availability and spending for the full spectrum of genetic tests, using unique data sources on test availability and commercial payer spending for privately insured populations, focusing particularly on tests measuring multiple genes in the period 2014-17. We found that there were approximately 75,000 genetic tests on the market, with about ten new tests entering the market daily. Prenatal tests accounted for the highest percentage of spending on genetic tests, and spending on hereditary cancer tests accounted for the second-highest. Our results provide insights for those interested in assessing genetic testing markets, test usage, and health policy implications, including current debates over the most appropriate regulatory and payer coverage mechanisms.

Original languageEnglish (US)
Pages (from-to)710-716
Number of pages7
JournalHealth Affairs
Volume37
Issue number5
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Genetic Testing
Information Storage and Retrieval
Human Genome
Health Policy
Population
Genes
Neoplasms

ASJC Scopus subject areas

  • Health Policy

Cite this

Phillips, K. A., Deverka, P. A., Hooker, G. W., & Douglas, M. P. (2018). Genetic test availability and spending: Where are we now? Where are we going? Health Affairs, 37(5), 710-716. https://doi.org/10.1377/hlthaff.2017.1427

Genetic test availability and spending : Where are we now? Where are we going? / Phillips, Kathryn A.; Deverka, Patricia A.; Hooker, Gillian W.; Douglas, Michael P.

In: Health Affairs, Vol. 37, No. 5, 01.01.2018, p. 710-716.

Research output: Contribution to journalArticle

Phillips, KA, Deverka, PA, Hooker, GW & Douglas, MP 2018, 'Genetic test availability and spending: Where are we now? Where are we going?', Health Affairs, vol. 37, no. 5, pp. 710-716. https://doi.org/10.1377/hlthaff.2017.1427
Phillips, Kathryn A. ; Deverka, Patricia A. ; Hooker, Gillian W. ; Douglas, Michael P. / Genetic test availability and spending : Where are we now? Where are we going?. In: Health Affairs. 2018 ; Vol. 37, No. 5. pp. 710-716.
@article{c690394ca3b44239a4fe7b55e2d6ef44,
title = "Genetic test availability and spending: Where are we now? Where are we going?",
abstract = "Genetic testing and spending on that testing have grown rapidly since the mapping of the human genome in 2003. However, it is not widely known how many tests there are, how they are used, and how they are paid for. Little evidence from large data sets about their use has emerged. We shed light on the issue of genetic testing by providing an overview of the testing landscape. We examined test availability and spending for the full spectrum of genetic tests, using unique data sources on test availability and commercial payer spending for privately insured populations, focusing particularly on tests measuring multiple genes in the period 2014-17. We found that there were approximately 75,000 genetic tests on the market, with about ten new tests entering the market daily. Prenatal tests accounted for the highest percentage of spending on genetic tests, and spending on hereditary cancer tests accounted for the second-highest. Our results provide insights for those interested in assessing genetic testing markets, test usage, and health policy implications, including current debates over the most appropriate regulatory and payer coverage mechanisms.",
author = "Phillips, {Kathryn A.} and Deverka, {Patricia A.} and Hooker, {Gillian W.} and Douglas, {Michael P.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1377/hlthaff.2017.1427",
language = "English (US)",
volume = "37",
pages = "710--716",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "5",

}

TY - JOUR

T1 - Genetic test availability and spending

T2 - Where are we now? Where are we going?

AU - Phillips, Kathryn A.

AU - Deverka, Patricia A.

AU - Hooker, Gillian W.

AU - Douglas, Michael P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Genetic testing and spending on that testing have grown rapidly since the mapping of the human genome in 2003. However, it is not widely known how many tests there are, how they are used, and how they are paid for. Little evidence from large data sets about their use has emerged. We shed light on the issue of genetic testing by providing an overview of the testing landscape. We examined test availability and spending for the full spectrum of genetic tests, using unique data sources on test availability and commercial payer spending for privately insured populations, focusing particularly on tests measuring multiple genes in the period 2014-17. We found that there were approximately 75,000 genetic tests on the market, with about ten new tests entering the market daily. Prenatal tests accounted for the highest percentage of spending on genetic tests, and spending on hereditary cancer tests accounted for the second-highest. Our results provide insights for those interested in assessing genetic testing markets, test usage, and health policy implications, including current debates over the most appropriate regulatory and payer coverage mechanisms.

AB - Genetic testing and spending on that testing have grown rapidly since the mapping of the human genome in 2003. However, it is not widely known how many tests there are, how they are used, and how they are paid for. Little evidence from large data sets about their use has emerged. We shed light on the issue of genetic testing by providing an overview of the testing landscape. We examined test availability and spending for the full spectrum of genetic tests, using unique data sources on test availability and commercial payer spending for privately insured populations, focusing particularly on tests measuring multiple genes in the period 2014-17. We found that there were approximately 75,000 genetic tests on the market, with about ten new tests entering the market daily. Prenatal tests accounted for the highest percentage of spending on genetic tests, and spending on hereditary cancer tests accounted for the second-highest. Our results provide insights for those interested in assessing genetic testing markets, test usage, and health policy implications, including current debates over the most appropriate regulatory and payer coverage mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=85046751710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046751710&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2017.1427

DO - 10.1377/hlthaff.2017.1427

M3 - Article

C2 - 29733704

AN - SCOPUS:85046751710

VL - 37

SP - 710

EP - 716

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 5

ER -